Date: Aug 13th, 2019

NanoMab Announces First Breast Cancer Patient Dosed in FIH of 99mTc-NM-02

Shanghai, China, August 13th, 2019. NanoMab today announced dosing of the first patients for its FIH trial of 99mTc-NM-02 in patients with breast cancer at SGH.

99mTc-NM-02 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of HER2 expression in patients before or during HER2 targeted treatment